ImmunoGen Inc. (IMGN)
Company Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.
The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate.
The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc.
ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| IPO Date | Nov 17, 1989 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 277 |
| CEO | Mark Joseph Enyedy |
Contact Details
Address: 830 Winter Street Waltham, Massachusetts United States | |
| Website | https://www.immunogen.com |
Stock Details
| Ticker Symbol | IMGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000855654 |
| CUSIP Number | 45253H101 |
| ISIN Number | US45253H1014 |
| Employer ID | 04-2726691 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark Joseph Enyedy | President, Chief Executive Officer & Director |
| Daniel S. Char J.D. | Senior Vice President, Chief Legal Officer & Secretary |
| Lauren A. White M.B.A. | Senior Vice President & Chief Financial Officer |
| Anabel Chan | Head of Investor Relations |
| Audrey Bergan | Senior Vice President & Chief HR Officer |
| Courtney O'Konek | Senior Director of Corporate Communications & Investor Relations |
| Dr. Michael J. Vasconcelles M.D., Ph.D. | Chief Medical Officer |
| Dr. Theresa G. Wingrove | Senior Vice President of Regulatory Affairs & Quality |
| Isabel Kalofonos | Senior Vice President & Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 22, 2024 | 15-12G | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 12, 2024 | 4 | Filing |
| Feb 12, 2024 | 4 | Filing |
| Feb 12, 2024 | 4 | Filing |
| Feb 12, 2024 | 4 | Filing |
| Feb 12, 2024 | 4 | Filing |
| Feb 12, 2024 | 4 | Filing |